10-K: TenX Keane Acquisition Files 2023 Annual Report, Details Merger Plans and Financials

TenX Keane Acquisition's 2023 annual report outlines its financial status, merger agreement with Citius Oncology, and efforts to extend its business combination deadline.

Summary

• TenX Keane Acquisition, a Cayman Islands company, filed its annual report for the fiscal year ended December 31, 2023.
• The company is a blank check company formed to effect a merger, share exchange, asset acquisition, or similar business combination.
• TenX Keane Acquisition has not generated any revenue and has incurred losses since inception.
• The company's net income for 2023 was $2,419,304, primarily from investment income on trust assets, offset by operating expenses.
• The company consummated its IPO in October 2022, raising $66 million, and a private placement of $3.94 million.
• A total of $67.32 million was placed in a trust account for the benefit of public shareholders.
• The company has extended its deadline to complete a business combination multiple times, incurring additional costs.
• TenX Keane Acquisition entered into a merger agreement with Citius Oncology in October 2023, expected to close in the first half of 2024.
• The merger will result in Citius Pharma receiving 67.5 million shares of the combined company, valued at $675 million, plus a $10 million cash contribution.
• The company has identified material weaknesses in its internal control over financial reporting related to accounting for accruals, related party transactions, and complex financial instruments.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress with the merger agreement, the financial losses, going concern issues, and internal control weaknesses raise significant concerns. The multiple extensions and reliance on sponsor loans also contribute to a negative sentiment.

Positives

• The company generated a net income of $2,419,304 in 2023, primarily from investment income.
• The merger agreement with Citius Oncology provides a clear path towards a business combination.
• The company has secured multiple extensions to complete its business combination, indicating flexibility.

Negatives

• The company has not generated any operating revenue and has incurred losses since inception.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has incurred significant costs in pursuit of its acquisition plans.
• There is substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.
• The company has relied on loans from the sponsor to fund operations.

Risks

• The company may not be able to complete its business combination within the extended timeframe.
• The company has material weaknesses in its internal control over financial reporting.
• The company's ability to continue as a going concern is in doubt.
• The company is reliant on the sponsor for loans and extensions.
• The merger with Citius Oncology is subject to shareholder approval and other closing conditions.
• The company may need to obtain additional financing to complete the business combination.
• The company's management team has no prior experience consummating a business combination for a blank check company.

Future Outlook

The company expects to complete its merger with Citius Oncology in the first half of 2024, subject to shareholder approval and other closing conditions. The company may need to obtain additional financing to complete the business combination.

Management Comments

• The management team is focused on completing the business combination with Citius Oncology.
• Management is working to address the identified material weaknesses in internal control over financial reporting.
• The management team believes that the merger will provide access to the U.S. capital markets.

Industry Context

The document reflects the typical challenges and timelines faced by SPACs in identifying and completing a business combination. The focus on Asia, excluding China, is a strategic choice given current geopolitical and regulatory considerations. The merger with a pharmaceutical company is a common target for SPACs seeking growth opportunities.

Comparison to Industry Standards

• The financial performance of TenX Keane Acquisition is typical for a SPAC in its pre-merger phase, with no operating revenue and reliance on trust account interest.
• The multiple extensions and associated costs are not uncommon for SPACs facing challenges in finding a suitable target.
• The merger agreement with Citius Oncology is similar to other SPAC transactions, involving a combination of equity and cash consideration.
• The identified material weaknesses in internal control over financial reporting are a concern and require remediation, which is not uncommon for newly public companies.
• The redemption rate of 2,287,923 shares at the January 17, 2024 meeting is a significant amount and indicates a lack of confidence from some shareholders.

Corporate Governance

Related Party Transactions

• The company pays an affiliate of the sponsor $10,000 per month for office space and administrative services.
• The company has received loans from the sponsor to fund operations and extend the business combination deadline.
• The sponsor has agreed to waive its redemption rights with respect to founder shares and public shares in connection with the business combination.
• The sponsor has agreed to waive its rights to liquidating distributions from the trust account with respect to the founder shares if the company fails to complete a business combination within the combination period.

Stakeholder Impact

• Shareholders face the risk of not receiving a return on their investment if the business combination is not completed.
• Shareholders may have their shares redeemed if the company does not complete a business combination within the required timeframe.
• Employees of the target company may be impacted by the merger.
• Creditors of the company may have claims against the trust account if the business combination is not completed.

Next Steps

• The company needs to obtain shareholder approval for the merger with Citius Oncology.
• The company needs to complete the domestication process to become a Delaware corporation.
• The company needs to address the material weaknesses in its internal control over financial reporting.
• The company needs to secure any additional financing required to complete the merger.
• The company needs to complete the merger with Citius Oncology by April 18, 2024, or extend the deadline again.

Key Dates

Keywords

SPAC, business combination, merger, acquisition, Citius Oncology, financial reporting, internal control, IPO, trust account, extension, redemption, sponsor, promissory note